Publication date: Jun 18, 2024
A recent clinical trial demonstrated that Bacille Calmette-GucE9rin (BCG) revaccination of adolescents reduced the risk of sustained infection with Mycobacterium tuberculosis (M. tb). In a companion phase 1b trial, HVTN 602/Aeras A-042, we characterize in-depth the cellular responses to BCG revaccination or to a H4:IC31 vaccine boost to identify T cell subsets that could be responsible for the protection observed. High-dimensional clustering analysis of cells profiled using a 26-color flow cytometric panel show marked increases in five effector memory CD4 T cell subpopulations (T) after BCG revaccination, two of which are highly polyfunctional. CITE-Seq single-cell analysis shows that the activated subsets include an abundant cluster of Th1 cells with migratory potential. Additionally, a small cluster of Th17 T cells induced by BCG revaccination expresses high levels of CD103; these may represent recirculating tissue-resident memory cells that could provide pulmonary immune protection. Together, these results identify unique populations of CD4 T cells with potential to be immune correlates of protection conferred by BCG revaccination.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | BCG vaccine |
| pathway | REACTOME | Infection with Mycobacterium tuberculosis |
| disease | MESH | infection |
| drug | DRUGBANK | Tretamine |
| disease | MESH | tuberculosis |
| pathway | KEGG | Tuberculosis |
| disease | MESH | Morbidity |
| disease | MESH | Infectious Diseases |
| drug | DRUGBANK | Creatinolfosfate |